

- The protein band Raf from mouse lung endothelial cells (MLECs) at the time points 0, 5, 10, 20, and 30 minutes in Figure 5A (bottom panel, lanes 1–5) of *JCI* 2005
 - the protein band FAK(P) from MRECs at the time points 20 and 40 minutes in Figure 7A (top panel, lanes 2 and 4) of *IOVS* 2009 and Figure 5A (top panel, lanes 2 and 4) of grant application R01 EY020539–01
 - the protein band FAK from MRECs at the time points 0, 20, 40, and 40 minutes in Figure 7A (bottom panel, lanes 1–5) of *IOVS* 2009 and Figure 5A (bottom panel, lanes 1–5) of grant application R01 EY020539–01
 - falsifying images of corneas by reusing and falsely labeling one image as two different experiments:
 - CNV cornea treated with arresten ($\alpha 1(IV)NC1$) in Figure 13 (right panel) of grant application R01 EY020539–01
 - CNV cornea treated with tumstatin ($\alpha 3(IV)NC1$) in Figure 3A (right panel) of *JCEO* Sub 2011
 - falsifying images of corneal sections by reusing and falsely labeling one image as two different experiments:
 - CNV cornea treated with arresten ($\alpha 1(IV)NC1$) in Figure 14 (right panel) of grant application R01 EY020539–01
 - CNV cornea treated with tumstatin ($\alpha 3(IV)NC1$) in Figure 4 (right panel) of *JCEO* Sub 2011
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as two different experiments:
 - MRECs treated with vascular endothelial growth factor (VEGF) and arresten ($\alpha 1(IV)NC1$) in Figure 2A (top right panel) of *IOVS* 2009 and Figure 2 (top right panel) of grant application R01 EY020539–01
 - HUVECs treated with only VEGF in Figure 1C (middle panel) of grant application R21 CA155796–01 and Figure 2C (second panel) of grant application R01 CA166195–01
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as two different experiments:
 - MRECs treated with VEGF in Figure 2A (top middle panel) of *IOVS* 2009 and Figure 2 (top middle panel) of grant application R01 EY020539–01
 - MRECs treated with basic fibroblast growth factor (bFGF) in Figure 3A (second panel) of *CER* 2010
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as three different experiments:
 - MRECs treated with bFGF and arresten ($\alpha 1NC1$) in Figure 3A (fourth panel) of *CER* 2010
 - MRECs treated with VEGF and arresten ($\alpha 1NC1$) in Figure 2A (bottom middle panel) of *IOVS* 2009 and Figure 2 (bottom middle panel) of grant application R01 EY020539–01
 - falsifying endothelial cell migration assays by reusing and falsely labeling one image as two different experiments:
 - MRECs treated with bFGF and 10 μ g/ml arresten ($\alpha 1NC1$) in Figure 3A (fifth panel) of *CER* 2010
 - HUVECs treated with VEGF and 0.5 μ M hexastatin ($\alpha 6NC1$) in Figure 1C (last panel) of grant application R21 CA155796–01
 - HUVECs treated with VEGF and 0.25 μ M hexastatin ($\alpha 6NC1$) in Figure 2C (third panel) of grant application R01 CA166195–01
- The following administrative actions have been implemented, beginning on August 24, 2019:
- (1) Respondent is debarred for a period of five (5) years from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376 *et seq.*) of Office of Management and Budget (OMB) Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”);
 - (2) Respondent is prohibited from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of five (5) years; and
 - (3) in accordance with 42 CFR 93 §§ 93.407(a)(1) and 93.411(b), HHS will send a notice of the findings and of the need for correction or retraction to the pertinent journals for each of the following:
 - *Biochemistry* 2000;39(42):12929–12938
 - *Proc. Natl. Acad. Sci. U.S.A.* 2003;100(8):4766–4771
 - *The Journal of Clinical Investigation* 2005;115(10):2801–2810
 - *Invest. Ophthalmol. Vis. Sci.* 2009;50(10):4567–4575
 - *Pharmaceutical Research* 2008;25(12):2731–2739
- *Scientific Reports* 2014;4(4136):1–9
 - *Current Eye Res.* 2010 Jan;35(1):44–55

Elisabeth A. Handley,
Interim Director, Office of Research Integrity.
 [FR Doc. 2019–24689 Filed 11–13–19; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center For Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA.

Date: January 24, 2020.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Victor Henriquez, Ph.D., Scientific Review Officer, Office of Scientific Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 20892–4878. 301–435–0813, henriqvu@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: November 7, 2019.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–24677 Filed 11–13–19; 8:45 am]

BILLING CODE 4140–01–P